Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes

[1]  R. Houot,et al.  T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. , 2009, Blood.

[2]  J. Weber,et al.  Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multipeptide vaccine for resected stages IIIC and IV melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Gajewski,et al.  Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma , 2009, Cancer Immunology, Immunotherapy.

[4]  S. O’Day,et al.  Phase I/II study of ipilimumab for patients with metastatic melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. Abe.  Lymphocytic infundibulo-neurohypophysitis and infundibulo-panhypophysitis regarded as lymphocytic hypophysitis variant , 2008, Brain Tumor Pathology.

[6]  N. Rose,et al.  Pituitary autoimmunity: 30 years later. , 2008, Autoimmunity reviews.

[7]  J. Allison,et al.  Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity , 2008, Cancer Immunology, Immunotherapy.

[8]  S. Steinberg,et al.  Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade , 2007, Clinical Cancer Research.

[9]  S. Rosenberg,et al.  Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis , 2007, Journal of immunotherapy.

[10]  J. Weber.  Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. , 2007, The oncologist.

[11]  R. Elashoff,et al.  An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites , 2007 .

[12]  L. Saltz,et al.  A phase II study of the anti-CTLA4 monoclonal antibody (mAb), CP-675,206, in patients with refractory metastatic adenocarcinoma of the colon or rectum , 2007 .

[13]  E. Small,et al.  A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer , 2007, Clinical Cancer Research.

[14]  P. Perros,et al.  Fatal inflammatory hypophysitis , 2007, Pituitary.

[15]  R. Thompson,et al.  Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. , 2006, Urologic oncology.

[16]  S. Rosenberg,et al.  Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma , 2006, Journal of immunotherapy.

[17]  S. Targan,et al.  Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected stages IIIC and IV melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  B. Kavanagh,et al.  A phase I trial of combination immunotherapy with CTLA-4 blockade and GM-CSF in hormone-refractory prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  F. Hodi,et al.  Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Rivera.  Lymphocytic hypophysitis: Disease spectrum and approach to diagnosis and therapy , 2006, Pituitary.

[21]  B. Comin-Anduix,et al.  Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Andrea Bolognesi,et al.  CTLA‐4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction , 2005, International journal of cancer.

[23]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study , 2005, Annals of Surgical Oncology.

[24]  S. Rosenberg,et al.  Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Rosenberg,et al.  Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010) , 2005 .

[26]  A. Pavlick,et al.  DURABLE RESPONSES AND LONG-TERM PROGRESSION- FREE SURVIVAL OBSERVED IN A PHASE II STUDY OF MDX- 010 ALONE OR IN COMBINATION WITH DACARBAZINE (DTIC) IN METASTATIC MELANOMA. , 2005 .

[27]  S. Rosenberg,et al.  Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. , 2005, Journal of immunotherapy.

[28]  E. Laws,et al.  Primary Hypophysitis: a Single-center Experience in 16 Cases Key Words @bullet Pituitary @bullet Hypophysitis @bullet Transsphenoidal Surgery @bullet Steroids @bullet Radiosurgery I , 2022 .

[29]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Thomas Davis,et al.  Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  G. Plant,et al.  Infundibulohypophysitis in a man presenting with diabetes insipidus and cavernous sinus involvement , 2001, Journal of neurology, neurosurgery, and psychiatry.

[32]  B. Foster,et al.  Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. , 2000, Cancer research.

[33]  D. Bernasconi,et al.  Lymphocytic hypophysitis. Case report. , 1999, Journal of neurosurgical sciences.

[34]  J. Allison,et al.  Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.

[35]  J. Beressi,et al.  Lymphocytic hypophysitis. A review of 145 cases. , 1999, Annales de medecine interne.

[36]  E. Seidman,et al.  Severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in an adolescent girl with a novel AIRE mutation: response to immunosuppressive therapy. , 1999, The Journal of clinical endocrinology and metabolism.

[37]  J. Allison,et al.  CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[39]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[40]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.